BRCA2 M1?

CI-VAR-00002571Explore in graph →NP_000050.2:p.Met1?NM_000059.3:c.3G>TClinVar 37871 CIViC 1248 rs80358650

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Ovarian Neoplasm1
BRCA2 M1?	Rucaparib	Predictive	C	Supports Sensitivity Response	—	accepted	EID2880 In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
37871	Pathogenic	criteria provided, multiple submitters, no conflicts	2	Breast-ovarian cancer, familial, susceptibility to, 2; Hereditary breast ovarian cancer syndrome; Breast and/or ovarian cancer; Hereditary cancer-predisposing syndrome	germline	6	Aug 06, 2024	clinvar